drugset / Trial / NCT00874887

A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

NCT00874887

Phase 4 Completed 66 enrolled Allergan
RandomizedParallel-groupSingle-blindBasic science

Summary

The purpose of this study is to assess if the presence of BAK in a fluoroquinolone in the study eye affects the development of resistant bacteria on the conjunctiva based upon changes in the surface flora over the course of 2 weeks of topical treatment in healthy adult subjects.

Timeline

Start
2009-03
Primary completion
2009-09
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gatifloxacin Small molecule 0.3 % Topical
Comparator Moxifloxacin Small molecule 0.5 % Topical

Indications

No indication recorded.